CD4+CD25+FOXP3+调节性T细胞预防移植物抗宿主病
异基因造血干细胞移植(HCT)可治疗血液恶性肿瘤和骨髓衰竭,但移植物抗宿主病(GVHD)和免疫无能限制了其应用。本文综述CD4+CD25+FoxP3+调节性T细胞在异基因HCT中的历史、临床前研究及成功转化,探讨其减少移植相关风险、扩大HCT适用人群的潜力。
要点
- GVHD是免疫失调反应,免疫抑制治疗和淋巴组织损伤会加重免疫功能障碍。
- CD4+CD25+FoxP3+调节性T细胞是免疫调节基本机制,其发现者获2025年诺贝尔生理学或医学奖。
- 该细胞在异基因HCT中的临床前研究及转化已有成功经验,有望降低移植风险。
核心结论
- CD4+CD25+FoxP3+调节性T细胞在异基因HCT中具有预防GVHD和改善免疫重建的转化潜力,有望降低移植相关风险并扩大HCT适用人群。
研究设计与样本
- 本文为综述,讨论CD4+CD25+FoxP3+调节性T细胞在异基因HCT领域的历史、临床前研究及成功转化。
主要发现
- GVHD是免疫失调反应,导致免疫功能障碍,并被免疫抑制药物及淋巴组织损伤进一步加剧。
- 免疫调节基本机制的阐明(先驱获2025年诺贝尔生理学或医学奖)为改善移植结局提供了新概念。
- 临床前研究和转化实践支持CD4+CD25+FoxP3+调节性T细胞在异基因HCT中的应用。
临床怎么用
- 关注CD4+CD25+FoxP3+调节性T细胞在异基因HCT中预防GVHD的转化应用,以降低移植相关风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (HCT) has benefited many patients with hematological malignancies and bone marrow failure states. However, graft-versus-host disease (GVHD) and immune incompetence remain significant challenges that limit the use of allogeneic HCT to patients with life-threatening, high-risk disorders because of the significant nonrelapse mortality associated with the treatment. With a greater understanding of the pathophysiology of GVHD, it has become apparent that this disorder represents a dysregulated immune reaction resulting in immune dysfunction, further exacerbated by treatment with immunosuppressive medications and injury to lymphoid tissues where immune recovery and tolerance develop. The emergence of fundamental mechanisms of immune regulation, whose pioneers received the 2025 Nobel Prize in Physiology or Medicine, has resulted in new concepts for improving outcomes for patients and offers the hope that, with a reduction in transplant-related risk, HCT can be offered to more patients with a broader range of immune-mediated disorders. In this review, the history, preclinical studies, and successful translation of CD4+CD25+FoxP3+ regulatory T cells in the context of allogeneic HCT are discussed.
引用
- Negrin RS, Meyer EH. CD4+CD25+FOXP3+ regulatory T cells to protect against graft-versus-host disease. Blood. 2026. PMID: 42378229. doi:10.1182/blood.2025029805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。